Sarilumab: all 47 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsNot yet recruitingNCT07836101Phase 2
• Phase 1b/2 Study of IV Sarilumab in Adult With RARecruitingNCT07704580Phase 1/2
• Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaRecruitingNCT07286214Phase 3
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingNCT05428007Phase 2
• A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)RecruitingNCT04333706Phase 1/2
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
• A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)RecruitingNCT02991469Phase 2
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Sarilumab COVID-19CompletedNCT04327388Phase 3Results posted
• Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARICompletedNCT04324073Phase 2/3Results posted
• Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19CompletedNCT04315298Phase 2/3Results posted
• Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisCompletedNCT04008069Phase 2Results posted
• Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic MastocytosisCompletedNCT03770273Phase 2Results posted
• Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaTerminatedNCT03600818Phase 3Results posted
• Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid ArthritisCompletedNCT03449758Phase 4Results posted
• An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)CompletedNCT02776735Phase 2Results posted
• Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)CompletedNCT02332590Phase 3Results posted
• To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)CompletedNCT02121210Phase 3Results posted
• Phase II Study to Analyze Sarilumab in Non-Infectious UveitisCompletedNCT01900431Phase 2Results posted
• To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)CompletedNCT01768572Phase 3Results posted
• An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus MethotrexateTerminatedNCT01764997Phase 3Results posted
• To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)CompletedNCT01709578Phase 3Results posted
• Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α BlockersTerminatedNCT01217814Phase 2Results posted
• Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)CompletedNCT01146652Phase 3Results posted
• Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing SpondylitisTerminatedNCT01118728Phase 2Results posted
• Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis PatientsCompletedNCT01061736Phase 2/3Results posted
• Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing SpondylitisCompletedNCT01061723Phase 2Results posted
• Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19WithdrawnNCT07196306Phase 2
• Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male SubjectsCompletedNCT06159452Phase 1
• A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.Active, not recruitingNCT05704634Phase 1
• Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingNCT05535738Phase 2/3
• Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisTerminatedNCT04842981Phase 1/2
• Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19Status unknownNCT04661527Phase 2
• Study on the Use of Sarilumab in Patients With COVID-19 InfectionWithdrawnNCT04386239Early Phase 1
• Clinical Trial of Sarilumab in Adults With COVID-19CompletedNCT04357860Phase 2
• Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)CompletedNCT04357808Phase 2
• Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)Status unknownNCT04350216Phase 4
• Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory FailureTerminatedNCT04322773Phase 2
• Study to Assess Sarilumab in Halting Progression of MorpheaWithdrawnNCT03679845Phase 1/2
• Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to BiologicsStatus unknownNCT03535402Phase 3
• Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid ArthritisCompletedNCT02404558Phase 1
• Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)CompletedNCT02097524Phase 1
• Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis PatientsCompletedNCT01328522Phase 1
• Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisCompletedNCT01055899Phase 1
• A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid ArthritisCompletedNCT01026519Phase 1
• A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis SubjectsCompletedNCT01011959Phase 1

← Sarilumab overview